NCCN Reinforces Prolaris' Value in Predicting Prostate Cancer Outcomes
The NCCN has endorsed the Prolaris prostate cancer prognostic test, reinforcing its position as a critical tool in prostate cancer prognostication.
Read More
Transforming Prostate Cancer Care Through Personalized Medicine
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Listen
FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC
The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
Novel immunotherapy FK-PC101 Explored in Prostate Cancer Trial
The phase 2 CELLVX-230 trial is assessing the potential of FK-PC101 to prevent prostate cancer recurrence and delay additional treatments post-surgery.
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
